We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Researchers Complete Re-creation of 1918 Virus

By HospiMedica staff writers
Posted on 28 Oct 2005
After almost 10 years of research, scientists have completed the re-creation of the influenza virus that took the lives of 20-50 million people worldwide in 1918 and 1919.

The work was conducted by scientists from the U.S. More...
Armed Forces Institute of Pathology (Washington, DC, USA), the U.S. Centers of Disease Control and Prevention (Atlanta, GA, USA), and Mount Sinai School of Medicine (New York, NY, USA). The findings have convinced the scientists that the 1918 virus began as an avian virus.

It has been difficult to study the 1918 virus since samples were not preserved at the time of the pandemic. Dr. Jeffery Taubenberger, chief of pathology at the U.S. Armed Forces Institute of Pathology, and his team have focused on publishing sequences for the genes of the virus, using materials preserved in the Alaskan permafrost and in the lungs of U.S. solders killed by the flu. They recently finished sequencing the three genes remaining. They have discovered 10 changes in amino acids that differ from other avian viruses, which suggest the virus might have mutated on its own to become transmissible in humans. The H5N1 avian virus that has so far claimed the lives of more than 50 people in Asia has already made five of these 10 changes. The team's work was published in the October 6, 2005, issue of Nature.

The other researchers, from Mount Sinai and the CDC, have reconstructed the virus by using reverse genetics, in order to learn what made it so lethal. The virus had the ability to enter cells deep in the lungs that flu viruses usually do not reach. The researchers focused on a gene in the re-created 1918 virus that allowed the virus to attach to cells and multiply. When that gene was removed, the virus lost its virulence. Moreover, certain genetic mutations of the virus have been found in the H5N1 strain, suggesting the new strain may follow a similar route. This team's work was published in the October 7, 2005, issue of Science.

According to Terrence Tumpey, a senior scientist at the CDC, the 1918 virus would be unlikely today to cause a pandemic. It is in the same family as those viruses many people have been exposed to over recent years, either by vaccination or natural infection, and thus they have developed some immune protection.

"This groundbreaking research helps unlock the mystery of the 1918 flu pandemic and is critically important in our efforts to prepare for pandemic influenza,” said CDC director Dr. Julie Gergerding.




Related Links:
Armed Forces Institute of Pathology
CDC
Mount Sinai

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
VTE Prevention System
Flowtron ACS900
Digital Color Doppler Ultrasound System
MS22Plus
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.